Haemophilia

Article	Citations
WFH Guidelines for the Management of Hemophilia, 3rd edition	906
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A	62
Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures	60
The role of telemedicine in the delivery of health care in the COVID‐19 pandemic	52
The World Federation of Hemophilia Annual Global Survey 1999‐2018	47
Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres	41
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US	37
Effects of emicizumab on APTT, one‐stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors	34
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	33
Synovitis and synovectomy in haemophilia	31
World Federation of Hemophilia Gene Therapy Registry	29
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC	29
Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia	29
Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic	29
Genetic causes of haemophilia in women and girls	28
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study	27
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project	26
Physiotherapy interventions for pain management in haemophilia: A systematic review	26
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns	26
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management	26
Low immunogenicity of emicizumab in persons with haemophilia A	26
European principles of care for women and girls with inherited bleeding disorders	25
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A	24
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)	24
Women and girls with haemophilia: Lessons learned	24

Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study	24
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data	24
The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation	24
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study	23
Emicizumab state‐of‐the‐art update	23
Evidence of a disability paradox in patient‐reported outcomes in haemophilia	23
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature	22
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?	22
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel	21
Clinical findings in a patient with haemophilia A affected by COVID‐19	21
The Function of extravascular coagulation factor IX in haemostasis	20
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery	20
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	20
Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A	20
Delivering on the promise of gene therapy for haemophilia	20
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?	19
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia	19
Haemophilia care in China: Achievements in the past decade	19
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	19
Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise	19
The COVID‐19 pandemic: New global challenges for the haemophilia community	19
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia	18
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study	17
Registry of patients with congenital bleeding disorders and COVID‐19 in Madrid	17
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays	17
How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types	17
Laboratory issues in gene therapy and emicizumab	17
Genetic mosaicism in haemophilia: A practical review to help evaluate the risk of transmitting the disease	16
von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis	16
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and	16
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study	16
Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies	15
In‐hospital management of persons with haemophilia and COVID‐19: Practical guidance	15
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review	15
Mental health disorders in haemophilia: Systematic literature review and meta‐analysis	15
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	15
Hemophilia gene therapy—New country initiatives	15
The 2021 von Willebrand disease guidelines: Clarity and controversy	15
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies	15
Physical activity levels in men with Haemophilia—A single centre UK survey	15
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	15
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study	15
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making	15
Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study	15
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice	15
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors	15
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS	14
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A	14
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis	14
Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey	14

Management of pregnancy in women with factor VII deficiency: A case series	14
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report	14
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment	14
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre	13
Management of COVID‐19‐associated coagulopathy in persons with haemophilia	13
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study	13
Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency	13
Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A	13
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies	13
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories	13
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study	12
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study	12
POSTER ABSTRACTS	12
Parental perspectives on gene therapy for children with haemophilia: The Exigency study	12
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays	12
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls	12
The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B	12
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU	12
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States	12
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable	12
3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross‐sectional comparative assessment of haemophilic arthropathy	11
Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies	11
Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the	11
The critical need for postmarketing surveillance in gene therapy for haemophilia	11
Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis	11
Management of comorbidities in haemophilia	11
Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach	11
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study	11
Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List	11
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France	11
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	11
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis	11
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India	11
Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise	11
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine	11
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review	11
Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres	11
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis	11
Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A	11
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	11
Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues	11
Gene therapy: Practical aspects of implementation	10
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors	10
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey	10
Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase	10
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint	10
Identification of new F8 deep intronic variations in patients with haemophilia A	10
All‐cause mortality and causes of death in persons with haemophilia: A systematic review and meta‐analysis	10
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years	10
Abstract	10
Real‐world analysis of haemophilia patients in China: A single centre's experience	10
The rising incidence of acquired haemophilia A in Germany	10
Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines	10
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC	10
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with hae	10
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen	10
Knee haemophilic arthropathy care in Chile: Midterm outcomes and complications after total knee arthroplasty	10
Big picture initiatives in bleeding disorders	10
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy	9
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies	9
Effects of a non‐pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive‐behavioural therapy associated with physiotherapy	9
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders	9
Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts	9
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study	9
Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea	9
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study	9
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline	9
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	9
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study	9
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A	9
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A	9
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes	9
Validation of a new instrument to measure disease‐related distress among patients with haemophilia	9
Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)	9
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	9
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	9
Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis	9
Diagnosis of haemophilia and other inherited bleeding disorders ‐ Is a new paradigm needed?	9
POSTER PRESENTATIONS	9
Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20‐year single‐surgeon cohort	9

Exercise capacity in people with haemophilia: A systematic review	9
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK	9
Prophylaxis in children with haemophilia in an evolving treatment landscape	9
Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy	8
Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy	8
Redefining prophylaxis in the modern era	8
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	8
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system	8
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward	8
Severe bleeding in a patient with factor XIII deficiency and COVID‐19	8
Biomarkers of bone disease in persons with haemophilia	8
Acquired bleeding disorders	8
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia	8
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience	8
Promoting physical activity for people with haemophilia in the age of new treatments	8
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics	8
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort	8
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	8
An evaluation of PROMIS health domains in adults with haemophilia: A cross‐sectional study	8
COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery	8
The effectiveness of manual therapy in addition to passive stretching exercises in the treatment of patients with haemophilic knee arthropathy: A randomized, single‐blind clinical trial	8
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	8
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A	8
Thrombomodulin in patients with mild to moderate bleeding tendency	7
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction	7
Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing	7
Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty‐four patients	7
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	7
Health technology assessment for gene therapies in haemophilia	7
Haemophilia gene therapy—Update on new country initiatives	7
Unravelling the knowledge, beliefs, behaviours and concerns of Persons with Haemophilia and their carriers in Senegal	7
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A	7
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?	7
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	7
Do we need all that emicizumab?	7
Low‐dose surgical prophylaxis: Optimization of use of World Federation of Hemophilia Humanitarian Aid donated clotting factor concentrates to developing countries	7
Depression and anxiety in persons with Von Willebrand disease	7
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors	7
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	7
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy	7
Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China	7
The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century	7
A comparison of MyPKFiT and WAPPS‐Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa	7
Patient satisfaction with US Hemophilia Treatment Center Care, Teams and Services: The First National Survey	7
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition	7
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making	7
Validation of the pictorial blood loss assessment chart using modern sanitary products	7
Show me the evidence: Effectiveness of low‐dose prophylaxis	7
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline	7
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures	7
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma	7
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis	7
Towards novel treatment options in von Willebrand disease	7
Acquired haemophilia A after alemtuzumab therapy	7
Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery	7
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires	7
The role of total ankle replacement in patients with haemophilia and end‐stage ankle arthropathy: A review	7
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary	7
An immediate hypersensitivity reaction induced by PEGylated recombinant factor VIII	6
Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027	6
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors	6
Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia	6
Ultrasound and patient self‐imaging in hemophilia	6
Long‐term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A	6
Severe haemophilia A children on low‐dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on‐demand treatment: A 6‐year follow‐u	6
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B	6
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	6
Substitution therapy	6
Real‐world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes	6
Reimbursing the value of gene therapy care in an era of uncertainty	6
Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study	6
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment	6
Optimal trough levels in haemophilia B: Raising expectations	6
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors	6
Inhibitors—Recent insights	6
Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects	6
Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathy	6
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?	6
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A	6
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)	6
Effectiveness of emicizumab in preventing life‐threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report	6
Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure:	6
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	6
Sports participation of patients with haemophilia in the COVID‐19 era: The Dutch experience	6
Early wound complications after orthopaedic surgery for haemophilia: What can we do more	6
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review	6
Inhibition of Fenton reaction is a novel mechanism to explain the therapeutic effect of intra‐articular injection of PRP in patients with chronic haemophilic synovitis	6
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study	6
Acquired bleeding disorders	6
Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study	6
Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany	6
Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A	6
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study	6
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia	6
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study	6